Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Paper from Dr.Shaw supporting why '113 is BIC...

Having proven at ASCO that '113 is the safest with equal or better response rates, and best activity in brain, it remains to be seen how durable the responses will be. Assuming pan-inhibition leads to durability, I think this article by Dr. Alice Shaw supports '113's potential as BIC, inhibiting the key mutations (L1196M, C1156Y, and L1152R) equal or better than Criz/LDK/Chugai, and a few novel ones (G1202R and T1151T) more effectively.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385512/

Interesting to me that Dr. Shaw is so silent on '113 when this study practically calls for a dual ALK/EFGR inhibitor, and possibly a KIT/ALK combo (did I just heard a call for Pona/'113 combo?). Don't you think a combo that targets ALK/ROS1/EGFR/RET/FGFR2/KIT might be effective in lung cancer?...just saying. If this were the old days it would be a miracle drug for lung cancer and every patient would start on it.